Combe B, Kivitz A, Tanaka Y, et al. - This study was undertaken to investigate the effectiveness and safety of the Janus kinase-1-preferential inhibitor filgotinib vs placebo or tumour necrosis factor-α inhibitor therapy in patients with active rheumatoid arthritis (RA) despite ongoing treatment with methotrexate (MTX). Researchers designed a 52-week, multicentre, double-blind, placebo-controlled and active-controlled phase III trial to analyze once-daily oral filgotinib in patients with RA randomised 3:3:2:3 to filgotinib 200 mg (FIL200) or filgotinib 100 mg (FIL100), subcutaneous adalimumab 40 mg biweekly, or placebo (through week 24), all with stable weekly background MTX. It has been reported that filgotinib improved RA signs and symptoms, improved physical function, inhibited radiographic progression and was well tolerated in patients with RA with inadequate response to MTX. It was shown that FIL200 was non-inferior to adalimumab.